Cart
sales@molnova.com
CFTR corrector 9
CAS No. 909861-78-5
CFTR corrector 9( —— )
Catalog No. M35450 CAS No. 909861-78-5
CFTR Corrector 9, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, is employed in the research of cystic fibrosis (CF) and related CFTR-associated disorders .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 62 | Get Quote |
|
| 5MG | 92 | Get Quote |
|
| 10MG | 147 | Get Quote |
|
| 25MG | 288 | Get Quote |
|
| 50MG | 431 | Get Quote |
|
| 100MG | 606 | Get Quote |
|
| 500MG | 1251 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCFTR corrector 9
-
NoteResearch use only, not for human use.
-
Brief DescriptionCFTR Corrector 9, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, is employed in the research of cystic fibrosis (CF) and related CFTR-associated disorders .
-
DescriptionCFTR corrector 9 (compound 42) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. CFTR corrector 9 can be used for researching cystic fibrosis (CF) and other CFTR associated disorders.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetCFTR
-
RecptorCFTR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number909861-78-5
-
Formula Weight298.29
-
Molecular FormulaC16H14N2O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (419.06 mM; Ultrasonic (<80°C)
-
SMILESCOc1cccc(c1)-c1cc(no1)C(=O)NCc1ccco1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bradley Tait, et al. Methods of modulating cftr activity. WO2014210159A1
molnova catalog
related products
-
GLPG-1837
GLPG-1837 (ABBV-974)?is a potent, orally available CFTR potentiator with EC50 of 3 nM and 339 nM on F508del and G551D CFTR, respectively.
-
VX661
VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.
-
Astressin 2B
Potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist (IC50 values are 1.3 and > 500 nM for CRF2 and CRF1 respectively). Antagonizes CRF2-mediated inhibition of gastric emptying.
